GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Henry Schein Inc (NAS:HSIC) » Definitions » Debt-to-EBITDA
中文

Henry Schein (Henry Schein) Debt-to-EBITDA

: 6.17 (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Henry Schein's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $494 Mil. Henry Schein's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,247 Mil. Henry Schein's annualized EBITDA for the quarter that ended in Dec. 2023 was $444 Mil. Henry Schein's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 6.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Henry Schein's Debt-to-EBITDA or its related term are showing as below:

HSIC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.83   Med: 1.33   Max: 3.13
Current: 3.13

During the past 13 years, the highest Debt-to-EBITDA Ratio of Henry Schein was 3.13. The lowest was 0.83. And the median was 1.33.

HSIC's Debt-to-EBITDA is ranked worse than
61.33% of 75 companies
in the Medical Distribution industry
Industry Median: 1.87 vs HSIC: 3.13

Henry Schein Debt-to-EBITDA Historical Data

The historical data trend for Henry Schein's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Henry Schein Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.09 1.38 1.14 1.55 3.13

Henry Schein Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.95 1.81 1.78 2.09 6.17

Competitive Comparison

For the Medical Distribution subindustry, Henry Schein's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henry Schein Debt-to-EBITDA Distribution

For the Medical Distribution industry and Healthcare sector, Henry Schein's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Henry Schein's Debt-to-EBITDA falls into.



Henry Schein Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Henry Schein's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(494 + 2247) / 877
=3.13

Henry Schein's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(494 + 2247) / 444
=6.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Henry Schein  (NAS:HSIC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Henry Schein Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Henry Schein's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Henry Schein (Henry Schein) Business Description

Traded in Other Exchanges
Address
135 Duryea Road, Melville, NY, USA, 11747
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
Executives
Stanley M Bergman director, officer: President and CEO C/O HENRY SCHEIN INC, 135 DURYEA ROAD, MELVILLE NY 11747
Bradford C Connett officer: CEO, NA Distribution Group C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Brous David B Jr officer: CEO, Strategic Business Group C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Walter Siegel officer: Senior VP & General Counsel C/O HENRY SCHEIN, INC, 135 DURYEA RD, MELVILLE NY 11747
James P Breslawski director, officer: Executive Vice President C/O HENRY SCHEIN INC, 135 DURYEA RD, MELVILLE NY 11747
Michael S Ettinger officer: SVP, General Counsel, Sec. C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Mark E Mlotek director, officer: SVP, Corp Bus Dev Group C/O HENRY SCHEIN INC, 135 DURYEA RD, MELVILLE NY 11747
Lorelei Mcglynn officer: SVP, Global HR & Fin. Oper. C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Gerald A Benjamin director, officer: Executive V.P and CAO C/O HENRY SCHEIN, INC, 135 DURYEA RD, MELVILLE NY 11747
Ronald N. South officer: SVP & Chief Financial Officer C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Philip A Laskawy director 9 CREAMER HILL ROAD, GREENWICH CT 06831
Kurt P Kuehn director C/O HENRY SCHEIN, INC, 135 DURYEA ROAD, MELVILLE NY 11747
Scott Philip Serota director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Reed Vaughn Tuckson director C/O UNITEDHEALTH GROUP INCORPORATED, 9900 BREN ROAD EAST, MINNETONKA MN 55123
Steven Paladino director, officer: Executive V.P. and CFO C/O HENRY SCHEIN INC, 135 DURYEA RD, MELVILLE NY 11747